Rare Diseases
Article
NORD to Partner Again With Hole in the Wall Gang Camp
Article
Rare Disease Day 2017 Will Highlight Research Theme
Article
NORD Seeks Input Regarding Patient Protections and ACA
News from the FDA/CDC
FDA approves Emflaza for Duchenne muscular dystrophy
Emflaza (deflazacort) becomes the first corticosteroid to be approved by the Food and Drug Administration for Duchenne muscular dystrophy.
Article
Huntington’s Disease Society of America Publishes 2016 Research Report
News from the FDA/CDC
West Nile virus accounted for 95% of domestic arboviral disease in 2015
The CDC reports that West Nile virus was the most common cause of domestically acquired arboviral disease in 2015.
From the Journals
Adolescents, boys, black children most likely to be hospitalized in SJS and TEN
Annual hospitalization rates in the United States for Stevens-Johnson syndrome and toxic epidermal necrolysis were shown to be higher in...
Conference Coverage
PERSIST-2 might allay some concerns about pacritinib in myelofibrosis
SAN DIEGO – Late-breaking results from the phase III PERSIST-2 trial may ease at least some safety concerns surrounding the use of pacritinib in...